New Roche Data to be Presented at ASCO Offers Further Hope for Cance...(Colorectal cancer -- Avastin: The fir...),Health

-- Avastin: The first presentation of data from Avastin-based therapy with

or without cetuximab (a drug which attacks cancer differently to

Avastin) in patients with metastatic colorectal cancer will be shared.

-- Avastin: Impressive long-term overall survival data at two years,

involving some 4,000 patients treated with Avastin first-line in

combination with a variety of chemotherapy regimens will confirm the

pivotal role that Avastin is now playing in patients with advanced

colorectal cancer. The results of the studies are significant because

over 50 percent of people diagnosed with colorectal cancer currently

die of the disease and these data show that improvements in survival

are achievable. (1)

Roche will present nearly 300 abstracts and posters at ASCO that demonstrate advances in other major cancers, as well as the data already described above in breast and colorectal. With one of the most comprehensive oncology research and development pipelines in the industry, Roche is striving to deliver even more treatment options in the fight against cancer. For example, Avastin's clinical trial program includes 40,000 patients worldwide.

Key sessions at which Roche data will be presented include:

Breast cancer

Avastin AVADO study. Miles D, et al, Sunday 1 June 2008,

Abstract No. LBA1011, oral 8:30am - 8:45am, E

presentation Hall D1

ASCO press briefing Saturday 31 May

2008, 9:00am, Press

Centre

Herceptin HER2-positive metastatic breast Tuesday 3 June 2008,

cancer study. Minckwitz G Von, et 8:00am - 12:00pm,

al, Abstract No. 1025, Poster No.
'/>"/>